Skip to main content

Advertisement

Table 1 Characteristics of studies in meta-analysis

From: Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials

Trials Treatment Dialysis modality Country No. patients Age,years Mean Baseline SBP,mmHg Mean Baseline DBP,mmHg Residual GFR,mL/min per 1.73 m2 Kt/V Mean Duration on dialysis,months follow-up, years
ACE-Is vs. placebo
 FOSIDIAL 2006 [9] ACE-I/Placebo HD France 397 67 146 77   1.3 49.2 2
ARBs vs. placebo
 SAFIR 2014 [11] ARB/Placebo HD Denmark 82 61 146 76 5.2   4.6 1
ACE-Is vs. active control
 Yilmaz 2010 [18] ACE-I/CCB HD Turkey 92 53.8 157 88   1.4 47 1
 Philip 2003 [14] ACE-I/Conventional ahtihypertensive agents PD China Kong Hong 60 58 151 83.5 3.55 2.08 10.5 1
 HDPAL 2014 [20] ACE-I/atenolol HD USA 200 53.1 151 87.1     1
ARBs vs. active control
 Suzuki 2008 [10] ARB/Conventional ahtihypertensive agents HD Japan 366 59.5 155 81   1.1 44.4 3
 Takahashi 2006 [8] ARB/CCB HD Japan 80 61 153 82    33.1 1.6
 OCTOPUS 2013 [19] ARB/Conventional ahtihypertensive agents HD Japan 469 59 159 80   1.2 88 3.5
 Suzuki 2004 [10] ARB/CCB PD Japan 34 63.5 165 76 4.3 1.97   24
 Wang J ARB/Conventional ahtihypertensive agents PD China 32 42 158 102 4.8 2.09 29 2.4
 Zhong H ARB/CCB PD China 44 45 134 83 4.5 1.97   1
  1. Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers; GFR, glomerular filtration rate; HD, hemodialysis; PD, peritoneal dialysis